What Researchers Did
American physicians described a rare genetic condition, poikiloderma with neutropenia, in a young adult woman who developed bilateral leg cellulitis and bone infection unresponsive to extensive antibiotic courses, treated with HBOT.
What They Found
After multiple antibiotic courses failed to resolve the chronic cellulitis and osteomyelitis, HBOT successfully treated the infections in this immunocompromised patient. This is the first reported use of HBOT in a patient with this condition.
What This Means for Canadian Patients
Patients with rare genetic conditions that cause low white blood cell counts and impaired immunity can develop chronic infections that do not respond to antibiotics. HBOT enhances the ability of remaining immune cells to fight infection, offering an option when standard treatments fail.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
A single case report in a rare disease provides only anecdotal evidence; the unique genetic and immune context makes generalization uncertain.